With 5.31 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.6 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $0.6265 whereas the lowest price it dropped to was $0.571. The 52-week range on SRXH shows that it touched its highest point at $3.15 and its lowest point at $0.47 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 0.82.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SRXH was up-trending over the past week, with a rise of 2.35%, but this was down by -5.25% over a month. Three-month performance dropped to -50.81% while six-month performance fell -64.73%. The stock lost -64.73% in the past year, while it has lost -76.72% so far this year.
Float and Shares Shorts:
At present, 11.67 million SRXH shares are outstanding with a float of 5.68 million shares on hand for trading. On 2025-06-13, short shares totaled 0.5 million, which was 495.0 higher than short shares on 1747267200. In addition to Mr. Adesh A. Vora Pharm.D. as the firm’s CEO & Director, Mr. Kent Cunningham serves as its President & Director.
Institutional Ownership:
Through their ownership of 0.00953 of SRXH’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SRXH reported revenue of $7159000.0 and operating income of -$1088000.0. The EBITDA in the recently reported quarter was -$1062000.0 and diluted EPS was -$0.067405.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$6.6 being high and -$6.6 being low. For SRXH, this leads to a yearly average estimate of -$6.6.
